# MIRROS (NCT02545283)

> A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02545283
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Hoffmann-La Roche
- Conditions: Leukemia, Myeloid, Acute
- Interventions: Cytarabine; Idasanutlin; Placebo
- Enrollment: 447
- Primary outcome: Overall Survival in TP53 WT Population

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=mirros-nct02545283